-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Medical Network reported on September 3 that the aftermath of the new crown epidemic has not yet dissipated, and sporadic domestic epidemics have rebounded
.
On the basis of ensuring the prevention and control of the epidemic, in the first half of 2021, the market sales of sample hospitals in China's key cities have increased significantly, with a year-on-year increase of approximately 17.
9%.
Taking into account the decline in revenue in the pharmaceutical industry caused by the epidemic in the first half of 2020, It can be said that in the first half of 2021, the entire pharmaceutical market in China has basically returned to the level before the epidemic
.
1 2012-2021 Q2 China's major cities drawing a sample hospital sales growth analysis we analyze each treatment according to ATC classification categories of the market, the first half of 2021, anti- cancer drugs and immune regulation inhibitors, and the whole digestive tract and systemic anti-infective drug metabolism The sales of drugs were 25.
3 billion yuan, 15.
8 billion yuan, and 15.
1 billion yuan in the top three.
Compared with the same period in 2020, the sales of anti-tumor drugs and immunosuppressants have increased significantly, exceeding 30%! Other treatment categories have basically achieved rapid growth
.
According to current trends, the second half of this year may usher in an "outbreak" of performance in various treatment categories
.
Figure 2 2021 Q1-Q2 and 2020 sales analysis of various treatment categories.
In the first half of 2021, there are 83 products with sales exceeding 250 million yuan, 24 products with sales exceeding 500 million yuan, and sales exceeding 1 billion.
There are only 6 kinds of yuan
.
We compiled the top 20 drugs in sales in the first half of 2021 and compared them with the sales rankings in 2020
.
It can be found that human albumin is still firmly in the "throne" and its position is unshakable.
It leads the list with a sales of 2.
38 billion yuan, which is 900 million yuan higher than the second place sodium chloride! The third place is Bevacizumab, which performed very well this year.
It beat Dezocine with a sales of 1.
18 billion yuan and became the third runner-up with a slight advantage
.
However, the traditional "three brothers" paclitaxel did not perform well in the first half of this year.
It only achieved sales of 1.
08 billion yuan and fell to sixth place.
.
In addition, iodixanol, compound amino acids, trastuzumab, piperacillin + tazobactam compound preparations, rituximab, oxaliplatin, and recombinant human platelet growth hormone have all made progress in varying degrees.
, Rituximab, recombinant human platelet growth factor, and oxaliplatin are the first to enter the list
.
The biggest dark horse osimertinib in 2020 seems to have weak stamina
.
It barely entered the list with sales of only 670 million yuan, expecting it to create another miracle .
Figure 3 Sales of TOP20 products in Q1-Q2 of 2021 Select the top 10 companies in terms of revenue in the first half of this year.
It is obvious that the growth of leading foreign companies is facing difficulties.
AstraZeneca, Pfizer, Roche, Bayer, and Novartis all have negative growth and pressure Sharp increase
.
Although AstraZeneca can barely maintain the number one position, Hengrui has already beaten Roche and Pfizer consecutively, rushing to the second place with a sales of 3.
67 billion yuan, which is only 210 million yuan behind AstraZeneca! In the second half of the year, we may be able to see Chinese pharmaceutical companies reach the top for the first time! For China's pharmaceutical companies, this is a historic event recorded in the annals of history
.
While Hengrui and AstraZeneca were inextricably beaten, Qilu Pharmaceutical, Yangtze River Pharmaceutical, CSPC, CP Tianqing Group occupied the fifth to eighth place, successfully squeezing Bayer and Novartis
.
The gap between Qilu Pharmaceutical and the fourth Pfizer is only 70 million yuan! my country's top 10 pharmaceutical companies are likely to be reshuffled.
According to the current situation, the total revenue of five foreign-funded companies is 13.
21 billion yuan, while the total revenue of five Chinese companies is 12.
52 billion yuan.
The difference between the two is only 690 million yuan! Regardless of whether it is a subdivided company or the overall performance, the gap between the two is significantly reduced, and "surpassing Britain and catching up with the United States" is now!
Figure 4 Sales of TOP10 companies in Q1-Q2 2021
.
On the basis of ensuring the prevention and control of the epidemic, in the first half of 2021, the market sales of sample hospitals in China's key cities have increased significantly, with a year-on-year increase of approximately 17.
9%.
Taking into account the decline in revenue in the pharmaceutical industry caused by the epidemic in the first half of 2020, It can be said that in the first half of 2021, the entire pharmaceutical market in China has basically returned to the level before the epidemic
.
1 2012-2021 Q2 China's major cities drawing a sample hospital sales growth analysis we analyze each treatment according to ATC classification categories of the market, the first half of 2021, anti- cancer drugs and immune regulation inhibitors, and the whole digestive tract and systemic anti-infective drug metabolism The sales of drugs were 25.
3 billion yuan, 15.
8 billion yuan, and 15.
1 billion yuan in the top three.
Compared with the same period in 2020, the sales of anti-tumor drugs and immunosuppressants have increased significantly, exceeding 30%! Other treatment categories have basically achieved rapid growth
.
According to current trends, the second half of this year may usher in an "outbreak" of performance in various treatment categories
.
Figure 2 2021 Q1-Q2 and 2020 sales analysis of various treatment categories.
In the first half of 2021, there are 83 products with sales exceeding 250 million yuan, 24 products with sales exceeding 500 million yuan, and sales exceeding 1 billion.
There are only 6 kinds of yuan
.
We compiled the top 20 drugs in sales in the first half of 2021 and compared them with the sales rankings in 2020
.
It can be found that human albumin is still firmly in the "throne" and its position is unshakable.
It leads the list with a sales of 2.
38 billion yuan, which is 900 million yuan higher than the second place sodium chloride! The third place is Bevacizumab, which performed very well this year.
It beat Dezocine with a sales of 1.
18 billion yuan and became the third runner-up with a slight advantage
.
However, the traditional "three brothers" paclitaxel did not perform well in the first half of this year.
It only achieved sales of 1.
08 billion yuan and fell to sixth place.
.
In addition, iodixanol, compound amino acids, trastuzumab, piperacillin + tazobactam compound preparations, rituximab, oxaliplatin, and recombinant human platelet growth hormone have all made progress in varying degrees.
, Rituximab, recombinant human platelet growth factor, and oxaliplatin are the first to enter the list
.
The biggest dark horse osimertinib in 2020 seems to have weak stamina
.
It barely entered the list with sales of only 670 million yuan, expecting it to create another miracle .
Figure 3 Sales of TOP20 products in Q1-Q2 of 2021 Select the top 10 companies in terms of revenue in the first half of this year.
It is obvious that the growth of leading foreign companies is facing difficulties.
AstraZeneca, Pfizer, Roche, Bayer, and Novartis all have negative growth and pressure Sharp increase
.
Although AstraZeneca can barely maintain the number one position, Hengrui has already beaten Roche and Pfizer consecutively, rushing to the second place with a sales of 3.
67 billion yuan, which is only 210 million yuan behind AstraZeneca! In the second half of the year, we may be able to see Chinese pharmaceutical companies reach the top for the first time! For China's pharmaceutical companies, this is a historic event recorded in the annals of history
.
While Hengrui and AstraZeneca were inextricably beaten, Qilu Pharmaceutical, Yangtze River Pharmaceutical, CSPC, CP Tianqing Group occupied the fifth to eighth place, successfully squeezing Bayer and Novartis
.
The gap between Qilu Pharmaceutical and the fourth Pfizer is only 70 million yuan! my country's top 10 pharmaceutical companies are likely to be reshuffled.
According to the current situation, the total revenue of five foreign-funded companies is 13.
21 billion yuan, while the total revenue of five Chinese companies is 12.
52 billion yuan.
The difference between the two is only 690 million yuan! Regardless of whether it is a subdivided company or the overall performance, the gap between the two is significantly reduced, and "surpassing Britain and catching up with the United States" is now!
Figure 4 Sales of TOP10 companies in Q1-Q2 2021
